United Way of Onslow County getting ready to host 'Vine and Dine' fundraiser
JACKSONVILLE, N.C. (WNCT)- United Way of Onslow County's annual 'Vine and Dine' fundraiser will take place on May 3rd with a new Kentucky Derby theme.
The event will be at the Waltons Distillery Event Center in Jacksonville with tickets on sale for $50 each. Patrons can try samples from local restaurants, distilleries, breweries and vineyards. There will also be live music, a viewing of the race and other derby themed activities.
The event will help fund United Way's programming, which includes but is not limited to giving grants to nonprofits, their Children Healthy Eating on Weekends (CHEW) program and their efforts to turn a vacant Jacksonville hotel into transitional housing.
'United Way is at the table for a lot. We are a busy around the clock, but we're at the table because we want to make a difference in the community and being in the community, we find out the need is there,' Director of Community Impact Diana King-Barnes said.
Individual tickets can be purchased here. They're also still looking for sponsorships, which can be found at the same link.
'There's no question we're here to serve the community in whatever capacity the community needs us at that moment,' President Raquel Painter said.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
5 hours ago
- Associated Press
Fifth Third Announces Three-Year, $20M Investment in North Nashville
CINCINNATI, June 20, 2025 /3BL/ - Fifth Third (NASDAQ: FITB) and Nashville leaders announced today that North Nashville will join the Fifth Third Neighborhood Program, bringing an influx of $20 million over three years to help revitalize the community. 'Fifth Third could not be more excited to bring our innovative Neighborhood Program to North Nashville,' said Kala Gibson, chief corporate responsibility officer for Fifth Third. 'We piloted our place-based economic development program back in 2019 and rolled it out in nine neighborhoods across our footprint in 2021. We have invested nearly $255 million since that time and witnessed generational, transformative change. We're thrilled about the opportunity to apply what we've learned and help North Nashville realize similar outcomes and impact.' In partnership with Affordable Housing Resources, Inc., Pathway Lending and United Way of Greater Nashville, Fifth Third and lead technical assistance partner Enterprise Community Partners will help community members implement their economic mobility roadmap that will help advance economic mobility and financial inclusion for the residents and businesses of North Nashville. To support this work, Fifth Third is pledging a $20 million investment in traditional financial and philanthropic capital in North Nashville over the next three years, including $1 million each to Affordable Housing Resources and the United Way from the Fifth Third Foundation. 'As a long-time resident of North Nashville I welcome this investment in our neighborhoods,' said Nashville Mayor Freddie O'Connell. 'We've been trying to shift how we invest in North Nashville. Recently, we've taken a special budgeting process and directed hundreds of thousands of dollars into four North Nashville Council districts. Then, we put $1 million directly into a multi-year effort anchored at Matthew Walker Comprehensive Health Center focused on lowering blood pressure. We've started to lower electric bills through a new insulation partnership with NES. And at least $7 million in federal funding to help North Nashville continue to recover from the long-term impacts of the 2020 tornado. 'Now we will amplify those investments with a $20 million commitment from Fifth Third that will result in community development through housing preservation, small business assistance, and vacant lot activation. Community members will see the results starting later this year,' Mayor O'Connell said. Nashville's economic mobility roadmap includes several key focus areas: growing housing and homeownership, such as by developing and preserving affordable housing; investing in small businesses and community wealth-building, such as by expanding access to capital and business planning; investing in people-based programs and services, such as by supporting education-to-career pathways; and investing in infrastructure and environmental priorities, such as by addressing tornado damage and highway impacts. 'I am thrilled that North Nashville has been selected for Fifth Third's Neighborhood Program,' said David Briggs, Tennessee region president for Fifth Third Bank. 'The North Nashville community embodies both the rich history of this city and the promise and challenges of its future. This investment of financial and intellectual capital illustrates Fifth Third's commitment to ensuring that all the members of the North Nashville community can share in its growth and truly make their lives a Fifth Third Better.' Fifth Third prioritizes broadening financial access and neighborhood revitalization through its Neighborhood Program, a community development initiative launched in 2021 which creates and implements innovative place-based strategies to effect positive change in historically disinvested neighborhoods across the Bank's 11-state consumer bank footprint. The program is pioneering a new place-based approach to community development by partnering with a lead partner organization, Enterprise Community Partners, and local organizations to build ecosystems that drive real change through both financial and social investments. This collective ecosystem approach is focused on identifying solutions to key challenges in partnership with the community, with the goal of creating lasting, transformative change. The place-based concept was piloted in 2019 in Detroit's Gratiot & Seven Mile neighborhood. Two years later, the program expanded into the Neighborhood Program, adding nine additional neighborhoods in seven states. Through the Neighborhood Program, Fifth Third has directly invested nearly $255 million across the nine neighborhoods. That investment helped catalyze over $200 million in additional investment. The result: $455 million in total Fifth Third-driven investments and tangible community impact, including: ### About Fifth ThirdFifth Third is a bank that's as long on innovation as it is on history. Since 1858, we've been helping individuals, families, businesses and communities grow through smart financial services that improve lives. Our list of firsts is extensive, and it's one that continues to expand as we explore the intersection of tech-driven innovation, dedicated people and focused community impact. Fifth Third is one of the few U.S.-based banks to have been named among Ethisphere's World's Most Ethical Companies® for several years. With a commitment to taking care of our customers, employees, communities and shareholders, our goal is not only to be the nation's highest performing regional bank, but to be the bank people most value and trust. Fifth Third Bank, National Association is a federally chartered institution. Fifth Third Bancorp is the indirect parent company of Fifth Third Bank and its common stock is traded on the NASDAQ® Global Select Market under the symbol 'FITB.' Investor information and press releases can be viewed at Deposit and credit products provided by Fifth Third Bank, National Association. Member FDIC. CONTACT Amanda Nageleisen (Media Relations) [email protected] Matt Curoe (Investor Relations) [email protected] | 513-534-2345 Visit 3BL Media to see more multimedia and stories from Fifth Third Bancorp
Business Wire
7 hours ago
- Business Wire
J.B. Poindexter & Co., Inc. Acquires Ambulance Manufacturing Leader Demers Braun Crestline Medix
HOUSTON--(BUSINESS WIRE)--J.B. Poindexter & Co., Inc. (JBPCO), a privately held North American manufacturing leader serving the commercial vehicle and specialty manufacturing industries, today announced the acquisition of Demers Braun Crestline Medix (DBCM). 'Our acquisition of DBCM aligns with JBPCO's long-term vision—building a platform of industry-leading companies with a shared commitment to quality, innovation, and customer service,' said John Poindexter, CEO and Chairman of JBPCO. Share Headquartered in Beloeil, Quebec (Canada), DBCM is one of North America's largest ambulance manufacturers with a strong presence across the U.S. and Canadian markets. Known for advanced innovation and paramedic-driven design, DBCM has delivered more than 70,000 units to over 40 countries and employs more than 1,500 team members across its operations. 'Our acquisition of DBCM aligns with JBPCO's long-term vision—building a platform of industry-leading companies with a shared commitment to quality, innovation, and customer service,' said John Poindexter, CEO and Chairman of JBPCO. 'As JBPCO celebrates its 40th anniversary, and each of the DBCM brands celebrates decades of dedication in the emergency vehicle industry, we are proud to bring together more than 500 years of combined manufacturing excellence across our portfolio of companies. DBCM has built a solid foundation, and we look forward to investing in its future, supporting the team, enhancing the products, and unlocking new opportunities for growth.' Demers recently launched its 11 th -generation ambulance platform and continues to set the bar in safety, design, and performance with paramedic-centric features like the FX Care Module. As part of JBPCO, the Company will continue to operate with brand autonomy while benefiting from expanded resources, shared capabilities, and a culture that values team member contributions. 'Joining JBPCO is a major milestone for our organization and our team,' said Alain Brunelle, CEO of Demers Braun Crestline Medix. 'We are united by a mission to improve lives, one relationship and one vehicle at a time—and this partnership ensures we can continue doing just that, with even greater scale and support.' JBPCO's total revenue will reach $3 billion with this acquisition, reinforcing its role as a cornerstone in the commercial and specialty vehicle manufacturing space—from last-mile delivery and work trucks to emergency response vehicles. About J.B. Poindexter & Co., Inc. J.B. Poindexter & Co., Inc. (JBPCO) is a privately held, diversified manufacturing company providing best-in-class commercial automotive and industrial solutions. JBPCO owns and operates a portfolio of leading business units including Morgan Truck Body, LLC; Morgan Olson, LLC; The Reading Truck Group, LLC; Truck Accessories Group, LLC d/b/a LEER Group; Masterack, LLC; EFP, LLC; Federal Eagle, LLC; and EAVX. JBPCO is headquartered in Houston, Texas and with the acquisition of DBCM, now employs more than 10,000 team members across North America. For more information, visit or connect on LinkedIn. Demers Braun Crestline Medix is one of North America's largest ambulance manufacturers, with a legacy of over 175 years across its four leading brands. Headquartered in Beloeil, Quebec, and operating in both Canada and the United States, the company designs and manufactures ambulances that meet the evolving needs of emergency service providers. Its brands—Demers, Braun, Crestline, and Medix—have delivered over 70,000 units in more than 40 countries. To learn more, visit and
Business Upturn
7 hours ago
- Business Upturn
INVESTOR DEADLINE: Rocket Pharmaceuticals, Inc. (RCKT) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, June 20, 2025 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the 'Class Period'), have until August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc. , No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges Rocket Pharmaceuticals as well as one of Rocket Pharmaceuticals' top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The Rocket Pharmaceuticals class action lawsuit alleges that defendants provided investors with material information concerning Rocket Pharmaceuticals' Phase 2 pivotal trial of RP-A501 for the treatment of Danon disease while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket Pharmaceuticals knew Serious Adverse Events, including death of participants enrolled in the study, were a risk. In particular, Rocket Pharmaceuticals amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders, according to the complaint. The Rocket Pharmaceuticals class action lawsuit further alleges that on May 27, 2025, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event, ultimately, death, while enrolled in the study following a substantive amendment to the protocol that Rocket Pharmaceuticals failed to disclose to investors at the time management made the revision. On this news, the price of Rocket Pharmaceuticals stock fell, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Rocket Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff in the Rocket Pharmaceuticals class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Rocket Pharmaceuticals class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Rocket Pharmaceuticals class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
